Gastroparesis Clinical Trial
Official title:
Role of Gastric Ultrasound in Preoperative Assessment of Gastric Volume in Longstanding Diabetic Patients. (Prospective Observational Study).
Background :An important risk factor for aspiration is gastric volume, determined in large
part by gastric emptying. Unfortunately, measuring gastric volume over time is not easy, and
scintigraphy has remained the gold standard technique for many years. Ultrasound has
progressively emerged as a useful substitute due to its reduced cost and ease of performance
Objectives:Assess whether ultrasonographic measurement of antral cross sectional area (CSA)
can be used reliably for the diagnosis of risk stomach which defined by a gastric content
volume at risk of clinical consequences for pulmonary aspiration (i.e., presence of solid
particles and/or gastric fluid volume >1.5 ml/kg) during the preoperative period in
longstanding diabetic patients.
Study population :
- -Longstanding diabetic patients (group D)
- -Non diabetic patients (group N) Study Design : Prospective observational study This
study will be conducted at Kasr alainy Hospital; Faculty of Medicine, Cairo
University.Patients scheduled for elective operations need General Anesthesia (GA) with
endotracheal intubation in theatre of general surgery Preoperative ultrasound to assess
gastric residual volume then general anesthesia induction will be Modified
Rapid-sequence Induction as follow; Group (D)/(N) : propofol 2-3mg/kg and fentanyl 1
µg/Kg followed by Rocuronium 0.6-1.2 mg/kg.
Suction of Gastric Contents by Nasogastric tube (18 french) will be inserted First set of
analysis will be comparing preoperative US findings in 2 groups.
Second set of analysis will be finding correlation between US findings and suction volume in
two groups.
Outcome parameters: To assess the residual gastric volume in longstanding diabetic patients
compared to non diabetic patients.
Sample Size ; was calculated as 48 patients (24) in each group.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
| Terminated |
NCT03285308 -
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
|
Phase 3 | |
| Completed |
NCT00733551 -
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
|
Phase 1 | |
| Completed |
NCT01650714 -
Endoscopic Full Thickness Biopsy, Gastric Wall.
|
N/A | |
| Completed |
NCT01452815 -
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
|
Phase 2 | |
| Completed |
NCT01039974 -
GSK962040 Drug-drug Interaction Study With Ketoconazole
|
Phase 1 | |
| Terminated |
NCT04844190 -
Use of EndoFLIP and Manometry Prior to G-POEM
|
N/A | |
| Enrolling by invitation |
NCT06215547 -
Medtronic Enterra II Neurostimulator
|
N/A | |
| Completed |
NCT04026997 -
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
|
Phase 2 | |
| Completed |
NCT00562848 -
A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040
|
Phase 1 | |
| Enrolling by invitation |
NCT04207996 -
Vagus Nerve Response in Gastroparesis Patients
|
||
| Completed |
NCT04607304 -
ABCA2 GIRMS Analytical Validation Clinical Performance Study
|
N/A | |
| Recruiting |
NCT06068114 -
Gastric Pathophysiology in Diabetes
|
||
| Completed |
NCT03259841 -
Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
|
||
| Active, not recruiting |
NCT04300127 -
Pioglitazone for Idiopathic Gastroparesis
|
Early Phase 1 | |
| Recruiting |
NCT01696734 -
Domperidone in Treating Patients With Gastrointestinal Disorders
|
Phase 3 | |
| Terminated |
NCT04635306 -
13C-Spirulina Nitrogen Content GEBT Study
|
N/A | |
| Withdrawn |
NCT02420925 -
Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis
|
N/A | |
| Recruiting |
NCT00777439 -
Domperidone for Refractory Gastrointestinal Disorders
|
N/A | |
| Terminated |
NCT00760461 -
Domperidone in Refractory Gastroparesis
|
Phase 2 |